Can Direct-Acting Antiviral Treatment Change the Immunologic Risk Profile in Patients Infected with Hepatitis C Virus Who Are on the Cadaveric Waiting List?

Creative Commons License

Bayraktar A. , Akgul S. U. , Bakkaloglu H. , Temurhan S. , Cinar Ç. , Ciftci H. S. , ...Daha Fazla

TRANSPLANTATION PROCEEDINGS, cilt.52, sa.1, ss.97-101, 2020 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 52 Konu: 1
  • Basım Tarihi: 2020
  • Doi Numarası: 10.1016/j.transproceed.2019.10.016
  • Sayfa Sayıları: ss.97-101


Background. In patients with hepatitis C virus (HCV) infection, the activation of the immune system by the virus or viral proteins leads to the production of numerous auto-antibodies and clinical manifestations. The objectives of this study were to investigate the relationship between HCV and anti-HLA antibodies, as well as the effect of viremia on the antibody response and of direct-acting antivirals (DAAs) on anti-HLA antibody persistence in patients on the waiting list for a cadaveric kidney transplant.